Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$131.82

0.29 (0.22%)

, BAYRY

Bayer

$133.06

0.01 (0.01%)

06:04
06/13/17
06/13
06:04
06/13/17
06:04

Bayer, J&J cleared of liability in second Xarelto trial, Reuters reports

Bayer (BAYRY) and Johnson & Johnson (JNJ) have been cleared of liability by a federal jury in the second trial stemming from thousands of lawsuits blaming injuries on Xarelto, a blood thinning drug, Reuters reports. Reference Link

JNJ

Johnson & Johnson

$131.82

0.29 (0.22%)

BAYRY

Bayer

$133.06

0.01 (0.01%)

  • 13

    Jun

  • 15

    Jun

  • 26

    Jun

JNJ Johnson & Johnson
$131.82

0.29 (0.22%)

06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
BAYRY Bayer
$133.06

0.01 (0.01%)

01/06/17
JPMS
01/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares are mispriced, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says Monsanto (MON) shares are mispriced and offer an attractive risk/reward proposition. A first catalyst for the shares would be regulatory agreement in the Dow Chemical (DOW)/DuPont (DD) transaction, Zekauskas tells investors in a research note. The analyst thinks a favorable resolution to the Dow/DuPont merger would be seen as improving the probability of the success of the Bayer/Monsanto transaction. He notes that Bayer has agreed to purchase Monsanto for $128 per share in cash, which represents 21% appreciation potential should the deal close by year-end. Zekauskas thinks a "reasonable floor" price for Monsanto shares, should the deal fail, is $102. He keeps an Overweight rating on the name with a $128 price target.
03/03/17
JPMS
03/03/17
NO CHANGE
Target $128
JPMS
Overweight
EU approvals of other ag deals may narrow Monsanto deal spread, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas said commentary from the CEOs of DuPont (DD) and Syngenta (SYT) and press reports from Europe suggest that their deals with Dow Chemical (DOW) and ChemChina, respectively, are likely to be approved. Approvals from Europe for those deals may "trigger a meaningful closing of the arbitrage spread" in Monsanto (MON) shares versus Bayer's (BAYRY) offer price, Zekauskas tells investors. He recommends buying Monsanto shares at current levels for this reason, adding that he believes the shares would only fall about 2.5%, or down to $112, in the event of the Bayer deal falling through. Zekauskas keeps an Overweight rating and $128 price target on Monsanto shares, which closed yesterday at just below $115 per share.
04/06/17
JPMS
04/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares offer 'excellent' risk/reward proposition, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says shares of Monsanto (MON) at current levels offer an "excellent" risk/reward proposition. The analyst views capital appreciation potential to the end of 2017 as 11% or a 15% annual return. He sees downside risk of only 3%, to $112 per share, in the event that Bayer (BAYRY) is not able to consummate the acquisition. Zekauskas has increased confidence in the deal closing following recent regulatory rulings and keeps an Overweight rating on the name with a $128 price target.
04/10/17
PIPR
04/10/17
NO CHANGE
Target $17
PIPR
Overweight
OncoMed price target lowered to $17 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for OncoMed (OMED) to $17 from $26 following two negative announcements, namely that the Phase II YOSEMITE study of demcizumab in first line pancreatic cancer failed and Bayer (BAYRY) returned rights for ipafricept and vantictumab. The analyst also notes that now partner Celgene (CELG) will review all data on demcizumab including Phase II DENALI non-small cell lung cancer data and Phase Ib combo data with KEYTRUDA, although he does not expect Celgene to exercise its option. Tenthoff reiterates an Overweight rating on OncoMed's shares.

TODAY'S FREE FLY STORIES

BLUE

bluebird bio

$171.15

3.25 (1.94%)

20:25
12/10/17
12/10
20:25
12/10/17
20:25
Conference/Events
bluebird bio to hold a webcast »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

DIS

Disney

$104.23

-0.19 (-0.18%)

, GOOG

Alphabet

$1,037.05

6.12 (0.59%)

20:06
12/10/17
12/10
20:06
12/10/17
20:06
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

DIS

Disney

$104.23

-0.19 (-0.18%)

GOOG

Alphabet

$1,037.05

6.12 (0.59%)

GOOGL

Alphabet Class A

$1,049.38

4.81 (0.46%)

DAL

Delta Air Lines

$53.46

0.05 (0.09%)

BRK.A

Berkshire Hathaway

$294,385.33

285.33 (0.10%)

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

PXD

Pioneer Natural

$155.90

1.65 (1.07%)

AMAT

Applied Materials

$51.43

-0.87 (-1.66%)

EPD

Enterprise Products

$24.94

0.25 (1.01%)

ALLY

Ally Financial

$28.65

0.28 (0.99%)

ANTM

Anthem

$224.85

1.21 (0.54%)

USFD

US Foods

$31.00

0.38 (1.24%)

TJX

TJX

$73.88

0.04 (0.05%)

ROST

Ross Stores

$76.89

0.19 (0.25%)

MBI

MBIA

$8.08

-0.01 (-0.12%)

CVS

CVS Health

$73.09

2 (2.81%)

T

AT&T

$36.73

0.56 (1.55%)

DISH

Dish

$48.59

-0.36 (-0.74%)

SNE

Sony

$45.79

0.04 (0.09%)

FOX

21st Century Fox

$32.97

-0.8 (-2.37%)

FOXA

21st Century Fox

$33.30

-0.88 (-2.57%)

TM

Toyota

$124.45

1.06 (0.86%)

SFTBY

SoftBank

$41.62

-0.02 (-0.05%)

GGP

GGP

$23.43

0.03 (0.13%)

BPY

Brookfield Property

$21.61

0.08 (0.37%)

HCA

HCA Healthcare

$84.84

-0.22 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

  • 14

    Dec

  • 09

    Jan

  • 23

    Jan

  • 07

    Feb

  • 18

    Mar

  • 08

    May

AKTX

Akari Therapeutics

$4.90

-0.14 (-2.78%)

19:25
12/10/17
12/10
19:25
12/10/17
19:25
Conference/Events
Akari Therapeutics to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

BMRN

BioMarin

$81.99

1.09 (1.35%)

, ALXN

Alexion

$114.46

7.68 (7.19%)

19:11
12/10/17
12/10
19:11
12/10/17
19:11
Recommendations
BioMarin, Alexion, Celgene analyst commentary at Piper Jaffray »

Piper Jaffray remains…

BMRN

BioMarin

$81.99

1.09 (1.35%)

ALXN

Alexion

$114.46

7.68 (7.19%)

CELG

Celgene

$106.09

3.36 (3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 08

    Jan

  • 18

    Jan

  • 28

    Feb

  • 25

    Mar

TWX

Time Warner

$90.71

0.34 (0.38%)

, CMCSA

Comcast

$37.95

0.06 (0.16%)

18:50
12/10/17
12/10
18:50
12/10/17
18:50
Hot Stocks
Box Office Battle: 'Coco' stays number 1 with $18.3M »

Disney (DIS) and…

TWX

Time Warner

$90.71

0.34 (0.38%)

CMCSA

Comcast

$37.95

0.06 (0.16%)

CMCSK

Comcast

SNE

Sony

$45.79

0.04 (0.09%)

FOX

21st Century Fox

$32.97

-0.8 (-2.37%)

FOXA

21st Century Fox

$33.30

-0.88 (-2.57%)

LGF.A

Lionsgate

$31.56

-0.07 (-0.22%)

DIS

Disney

$104.23

-0.19 (-0.18%)

VIAB

Viacom

$29.29

-0.35 (-1.18%)

VIA

Viacom

$34.00

-0.25 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

18:38
12/10/17
12/10
18:38
12/10/17
18:38
Periodicals
Volkswagen CEO suggests ending diesel vehicles subsidies, NY Times reports »

Volkswagen CEO said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$84.84

-0.22 (-0.26%)

18:35
12/10/17
12/10
18:35
12/10/17
18:35
Periodicals
Hospital giants in talks to merge, WSJ reports »

Ascension and Providence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

18:27
12/10/17
12/10
18:27
12/10/17
18:27
Periodicals
Volkswagen executive may ask to serve sentence in Germany, Reuters says »

Volkswagen executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGP

GGP

$23.43

0.03 (0.13%)

, BPY

Brookfield Property

$21.61

0.08 (0.37%)

18:21
12/10/17
12/10
18:21
12/10/17
18:21
Periodicals
Mall owner GGP rejects Brookfield Property buyout offer, Reuters reports »

U.S. mall owner GGP (GGP)…

GGP

GGP

$23.43

0.03 (0.13%)

BPY

Brookfield Property

$21.61

0.08 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRC

AtriCure

$17.96

0.01 (0.06%)

18:16
12/10/17
12/10
18:16
12/10/17
18:16
Recommendations
AtriCure analyst commentary at Piper Jaffray »

Piper Jaffray remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

KPTI

Karyopharm

$11.11

0.48 (4.52%)

18:11
12/10/17
12/10
18:11
12/10/17
18:11
Hot Stocks
Karyopharm presents positive phase 1/2 Eltanexor data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$11.11

0.48 (4.52%)

18:09
12/10/17
12/10
18:09
12/10/17
18:09
Hot Stocks
Karyopharm presents positive Selinexor data from STOMP study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

18:05
12/10/17
12/10
18:05
12/10/17
18:05
Hot Stocks
Agios Pharmaceuticals presents updated data from DRIVE PK study »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ICL

ICL

$4.03

-0.07 (-1.71%)

18:01
12/10/17
12/10
18:01
12/10/17
18:01
Hot Stocks
ICL completes sale of 50% share of IDE Technologies for $167M »

ICL announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$32.74

0.52 (1.61%)

17:52
12/10/17
12/10
17:52
12/10/17
17:52
Hot Stocks
AstraZeneca Calquence shows potential in chronic lymphocytic leukemia trials »

AstraZeneca and Acerta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZIOP

Ziopharm

$4.43

0.09 (2.07%)

, XON

Intrexon

$13.28

0.16 (1.22%)

17:48
12/10/17
12/10
17:48
12/10/17
17:48
Hot Stocks
Ziopharm announces presentation of data from T-Cell Therapy programs »

Ziopharm Oncology (ZIOP)…

ZIOP

Ziopharm

$4.43

0.09 (2.07%)

XON

Intrexon

$13.28

0.16 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:45
12/10/17
12/10
17:45
12/10/17
17:45
Hot Stocks
bluebird bio announces results from LentiGlobin study in Severe Sickle Cell »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:37
12/10/17
12/10
17:37
12/10/17
17:37
Hot Stocks
bluebird bio presents new data from clinical studies of LentiGlobin Gene Therapy »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

VSTM

Verastem

$4.33

0.36 (9.07%)

17:35
12/10/17
12/10
17:35
12/10/17
17:35
Hot Stocks
Verastem announces phase 3 DUO study met primary endpoint »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

CELG

Celgene

$106.09

3.36 (3.27%)

, BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:30
12/10/17
12/10
17:30
12/10/17
17:30
Hot Stocks
Celgene, bluebird bio announce updated results from CRB-401 Phase 1 study »

Celgene (CELG) and…

CELG

Celgene

$106.09

3.36 (3.27%)

BLUE

bluebird bio

$171.15

3.25 (1.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

GILD

Gilead

$74.22

1.5 (2.06%)

17:22
12/10/17
12/10
17:22
12/10/17
17:22
Hot Stocks
Kite announces long-term data from pivotal ZUMA-1 study of Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

EPZM

Epizyme

$13.25

0.25 (1.92%)

17:18
12/10/17
12/10
17:18
12/10/17
17:18
Hot Stocks
Epizyme presents new biomarker data on Tazemetostat »

Epizyme announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$51.47

0.76 (1.50%)

17:16
12/10/17
12/10
17:16
12/10/17
17:16
Hot Stocks
Study shows Bioverativ Eloctate has potential to improve bleed protection »

Bioverativ and Swedish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$12.37

-0.505 (-3.92%)

17:04
12/10/17
12/10
17:04
12/10/17
17:04
Hot Stocks
Syros Pharmaceuticals announces new preclinical data on SY-1365 »

Syros Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SYRS

Syros Pharmaceuticals

$12.37

-0.505 (-3.92%)

17:00
12/10/17
12/10
17:00
12/10/17
17:00
Hot Stocks
Syros Pharmaceuticals announces initial data from phase 2 trial of SY-1425 »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.